Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans

PierMarco Piatti, Lucilla D. Monti, Morena Conti, Laura Baruffaldi, Laura Galli, Chuong V. Phan, Barbara Guazzini, Antonio E. Pontiroli, Guido Pozza

Research output: Contribution to journalArticle

Abstract

The purpose of the study was to evaluate fasting endothelin-1 levels in subjects with syndrome X, in subjects with insulinoma, and in normal subjects. The single and synergistic contributions of insulin and triglyceride levels to endothelin-1 release were studied in normal subjects. This was achieved by the evaluation of endothelin-1 levels in response to an insulin bolus combined with a euglycemic clamp (protocol A) and during intralipid (test 1) or saline (test 2) infusions lasting 360 min (protocol B). In protocol B, a euglycemic two-step hyperinsulinemic (25 and 125 mU · kg-1 · h-1) clamp was started at 120 min. Subjects with syndrome X showed significantly higher endothelin-1 levels than normal subjects and subjects with insulinoma (7.22 ± 0.89 vs. 2.61 ± 0.38 and 2.49 ± 0.24 pg/ml, P <0.01). After an insulin bolus, endothelin-1 levels peaked at 10 min (3.71 ± 0.96 pg/ml). The incremental area of endothelin-1 was significantly higher after insulin than after a saline bolus. In test 1, an acute increase in triglyceride levels significantly enhanced endothelin-1 levels, which were further increased by the synergistic contribution of high insulin and triglyceride levels. In test 2, endothelin-1 release was achieved at high insulin levels but remained significantly lower than in test 1. In conclusion, subjects with syndrome X showed higher endothelin-1 levels than normal subjects and subjects with insulinoma. These levels were reproduced in normal subjects by a simultaneous increase in insulin and triglyceride levels.

Original languageEnglish
Pages (from-to)316-321
Number of pages6
JournalDiabetes
Volume45
Issue number3
Publication statusPublished - Mar 1996

Fingerprint

Hypertriglyceridemia
Hyperinsulinism
Endothelin-1
Insulin
Insulinoma
Triglycerides
Glucose Clamp Technique
Fasting

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. / Piatti, PierMarco; Monti, Lucilla D.; Conti, Morena; Baruffaldi, Laura; Galli, Laura; Phan, Chuong V.; Guazzini, Barbara; Pontiroli, Antonio E.; Pozza, Guido.

In: Diabetes, Vol. 45, No. 3, 03.1996, p. 316-321.

Research output: Contribution to journalArticle

Piatti, P, Monti, LD, Conti, M, Baruffaldi, L, Galli, L, Phan, CV, Guazzini, B, Pontiroli, AE & Pozza, G 1996, 'Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans', Diabetes, vol. 45, no. 3, pp. 316-321.
Piatti, PierMarco ; Monti, Lucilla D. ; Conti, Morena ; Baruffaldi, Laura ; Galli, Laura ; Phan, Chuong V. ; Guazzini, Barbara ; Pontiroli, Antonio E. ; Pozza, Guido. / Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans. In: Diabetes. 1996 ; Vol. 45, No. 3. pp. 316-321.
@article{675abb056560467f827d568d87d39c54,
title = "Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans",
abstract = "The purpose of the study was to evaluate fasting endothelin-1 levels in subjects with syndrome X, in subjects with insulinoma, and in normal subjects. The single and synergistic contributions of insulin and triglyceride levels to endothelin-1 release were studied in normal subjects. This was achieved by the evaluation of endothelin-1 levels in response to an insulin bolus combined with a euglycemic clamp (protocol A) and during intralipid (test 1) or saline (test 2) infusions lasting 360 min (protocol B). In protocol B, a euglycemic two-step hyperinsulinemic (25 and 125 mU · kg-1 · h-1) clamp was started at 120 min. Subjects with syndrome X showed significantly higher endothelin-1 levels than normal subjects and subjects with insulinoma (7.22 ± 0.89 vs. 2.61 ± 0.38 and 2.49 ± 0.24 pg/ml, P <0.01). After an insulin bolus, endothelin-1 levels peaked at 10 min (3.71 ± 0.96 pg/ml). The incremental area of endothelin-1 was significantly higher after insulin than after a saline bolus. In test 1, an acute increase in triglyceride levels significantly enhanced endothelin-1 levels, which were further increased by the synergistic contribution of high insulin and triglyceride levels. In test 2, endothelin-1 release was achieved at high insulin levels but remained significantly lower than in test 1. In conclusion, subjects with syndrome X showed higher endothelin-1 levels than normal subjects and subjects with insulinoma. These levels were reproduced in normal subjects by a simultaneous increase in insulin and triglyceride levels.",
author = "PierMarco Piatti and Monti, {Lucilla D.} and Morena Conti and Laura Baruffaldi and Laura Galli and Phan, {Chuong V.} and Barbara Guazzini and Pontiroli, {Antonio E.} and Guido Pozza",
year = "1996",
month = "3",
language = "English",
volume = "45",
pages = "316--321",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "3",

}

TY - JOUR

T1 - Hypertriglyceridemia and hyperinsulinemia are potent inducers of endothelin-1 release in humans

AU - Piatti, PierMarco

AU - Monti, Lucilla D.

AU - Conti, Morena

AU - Baruffaldi, Laura

AU - Galli, Laura

AU - Phan, Chuong V.

AU - Guazzini, Barbara

AU - Pontiroli, Antonio E.

AU - Pozza, Guido

PY - 1996/3

Y1 - 1996/3

N2 - The purpose of the study was to evaluate fasting endothelin-1 levels in subjects with syndrome X, in subjects with insulinoma, and in normal subjects. The single and synergistic contributions of insulin and triglyceride levels to endothelin-1 release were studied in normal subjects. This was achieved by the evaluation of endothelin-1 levels in response to an insulin bolus combined with a euglycemic clamp (protocol A) and during intralipid (test 1) or saline (test 2) infusions lasting 360 min (protocol B). In protocol B, a euglycemic two-step hyperinsulinemic (25 and 125 mU · kg-1 · h-1) clamp was started at 120 min. Subjects with syndrome X showed significantly higher endothelin-1 levels than normal subjects and subjects with insulinoma (7.22 ± 0.89 vs. 2.61 ± 0.38 and 2.49 ± 0.24 pg/ml, P <0.01). After an insulin bolus, endothelin-1 levels peaked at 10 min (3.71 ± 0.96 pg/ml). The incremental area of endothelin-1 was significantly higher after insulin than after a saline bolus. In test 1, an acute increase in triglyceride levels significantly enhanced endothelin-1 levels, which were further increased by the synergistic contribution of high insulin and triglyceride levels. In test 2, endothelin-1 release was achieved at high insulin levels but remained significantly lower than in test 1. In conclusion, subjects with syndrome X showed higher endothelin-1 levels than normal subjects and subjects with insulinoma. These levels were reproduced in normal subjects by a simultaneous increase in insulin and triglyceride levels.

AB - The purpose of the study was to evaluate fasting endothelin-1 levels in subjects with syndrome X, in subjects with insulinoma, and in normal subjects. The single and synergistic contributions of insulin and triglyceride levels to endothelin-1 release were studied in normal subjects. This was achieved by the evaluation of endothelin-1 levels in response to an insulin bolus combined with a euglycemic clamp (protocol A) and during intralipid (test 1) or saline (test 2) infusions lasting 360 min (protocol B). In protocol B, a euglycemic two-step hyperinsulinemic (25 and 125 mU · kg-1 · h-1) clamp was started at 120 min. Subjects with syndrome X showed significantly higher endothelin-1 levels than normal subjects and subjects with insulinoma (7.22 ± 0.89 vs. 2.61 ± 0.38 and 2.49 ± 0.24 pg/ml, P <0.01). After an insulin bolus, endothelin-1 levels peaked at 10 min (3.71 ± 0.96 pg/ml). The incremental area of endothelin-1 was significantly higher after insulin than after a saline bolus. In test 1, an acute increase in triglyceride levels significantly enhanced endothelin-1 levels, which were further increased by the synergistic contribution of high insulin and triglyceride levels. In test 2, endothelin-1 release was achieved at high insulin levels but remained significantly lower than in test 1. In conclusion, subjects with syndrome X showed higher endothelin-1 levels than normal subjects and subjects with insulinoma. These levels were reproduced in normal subjects by a simultaneous increase in insulin and triglyceride levels.

UR - http://www.scopus.com/inward/record.url?scp=0030059723&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030059723&partnerID=8YFLogxK

M3 - Article

C2 - 8593936

AN - SCOPUS:0030059723

VL - 45

SP - 316

EP - 321

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 3

ER -